comparemela.com
Home
Live Updates
JW Therapeutics Announces Initiation of Clinical Study of Carteyva® in First-line Treatment in Patients with High-Risk Large B-Cell Lymphoma : comparemela.com
JW Therapeutics Announces Initiation of Clinical Study of Carteyva® in First-line Treatment in Patients with High-Risk Large B-Cell Lymphoma
/PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing...
Related Keywords
China ,
Shanghai ,
United Kingdom ,
Ying Zhao ,
A Bristol Myers Squibb ,
National Significant New Drug Development Program ,
International Prognostic Index ,
Intergroup Trial Alliance ,
China National Medical Products Administration ,
China Association Lymphoma Committee ,
Anti Cancer Association Lymphoma Committee ,
Chinj Oncol ,
Relmacabtagene Autoleucel Injection ,
Juno Therapeutics ,
Bristol Myers Squibb ,
Jw Therapeutics ,
Health Care Amp Hospitals ,
Medical Pharmaceuticals ,
Biotechnology ,
Pharmaceuticals ,
Clinical Trials Amp Medical Discoveries ,
comparemela.com © 2020. All Rights Reserved.